Literature DB >> 3348239

Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis.

B S Bloom1.   

Abstract

We conducted a study to determine the costs of caring for patients with arthritis. Data were obtained from the Medicaid Management Information System (MMIS) of Washington, DC. A retrospective analysis was undertaken of all direct medical costs related to individual Medicaid recipients who obtained treatment for arthritis. First, all data were adjusted for patient compliance with nonsteroidal anti-inflammatory drugs (NSAIDs). Second, we determined the actual expenditure of treating arthritis. Last, the medical costs of treating adverse gastrointestinal side effects were examined. There was a linear relationship between compliance and pharmaceutical dose schedule per diem. Treatment costs per quarter were $145; 54 percent of the cost was for NSAIDs with the remainder equally divided between physician and hospital costs. Approximately 25 percent of the population experienced NSAID-related gastrointestinal side effects that required further medical care. The per-quarter mean cost of treating these adverse gastrointestinal drug reactions was $66 per person, which added nearly 46 percent to the per-quarter mean cost of treatment. The total cost of treating patients with arthritis therefore averaged $211 per quarter. Nearly one third of overall cost went to provide medical care to the 25 percent of the population who experienced adverse reactions, and slightly more than two thirds went towards treating the disease itself. Overall costs of treating adverse drug reactions were accounted for by pharmaceuticals (about 42 percent), usually the histamine (H2)-receptor antagonist cimetidine, rare but expensive inpatient hospital care (about 38 percent) and physician visits (about 20 percent).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3348239     DOI: 10.1016/0002-9343(88)90250-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  28 in total

Review 1.  Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective.

Authors:  C Chevat; B M Peña; M J Al; F F Rutten
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Daily regimen and compliance with treatment.

Authors:  B S Bloom
Journal:  BMJ       Date:  2001-09-22

Review 3.  Preventing NSAID-induced gastrointestinal toxicity. Economic considerations, methodological problems and results.

Authors:  G de Pouvourville
Journal:  Pharmacoeconomics       Date:  1995-02       Impact factor: 4.981

4.  Cost, benefits and unintended gastrointestinal side effects of pharmaceutical therapy.

Authors:  B S Bloom
Journal:  Pharmacoeconomics       Date:  1992-03       Impact factor: 4.981

Review 5.  Ultrasound-guided interventional procedures around the shoulder.

Authors:  Carmelo Messina; Giuseppe Banfi; Davide Orlandi; Francesca Lacelli; Giovanni Serafini; Giovanni Mauri; Francesco Secchi; Enzo Silvestri; Luca Maria Sconfienza
Journal:  Br J Radiol       Date:  2015-09-23       Impact factor: 3.039

Review 6.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 7.  NSAID-induced gastrointestinal damage. Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus.

Authors:  G D Champion; P H Feng; T Azuma; D E Caughey; K H Chan; S Kashiwazaki; H C Liu; A R Nasution; M Nobunaga; S Prichanond; T P Torralba; V Udom; D Utis; S R Wang; W S Wong; D J Yang; M C Yoo
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

8.  Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta.

Authors:  D B Hogan; N R Campbell; R Crutcher; P Jennett; N MacLeod
Journal:  CMAJ       Date:  1994-08-01       Impact factor: 8.262

9.  Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.

Authors:  Andrew Moore; Ceri Phillips; Elke Hunsche; James Pellissier; Simone Crespi
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  Current state of therapy for pain and inflammation.

Authors:  Steven B Abramson; Arthur L Weaver
Journal:  Arthritis Res Ther       Date:  2005-09-15       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.